Content about Chemistry

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating some disorders that harm the body's ability to remove ammonia from the blood, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare cholesterol disorder, the agency said.

The FDA announced the approval of Kynamro (mipomersen sodium), made by Genzyme for the treatment of homozygous familial hypercholesterolemia, or HoFH. Kynamro has been approved as an orphan drug, a designation the FDA gives to drugs that treat diseases affecting fewer than 200,000 people.

CHARLESTON, S.C. — Startup company GetAwayGrey is offering an alternative way to battle gray hair with its new nutraceutical multivitamin that is designed to reverse and prevent gray hair.

The product is an alternative to the use of hair dyes, which contain irritating and potentially toxic chemicals.

GetAwayGrey, which is an alternative to the use of hair dyes, works on an entirely different principle than dyes and chemicals by addressing the underlying cause of grey hair: Hydrogen peroxide removes pigment from hair before it grows.

SILVER SPRING, Md. — The Food and Drug Administration has approved three new drugs for Type 2 diabetes made by Takeda, the agency said Friday.

The FDA announced the approval of Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone) tablets.

Alogliptin is a new active ingredient, while metformin and pioglitazone are drugs already on the market.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug used for treating allergies, the generic drug maker said Friday.

The Indian drug maker announced the launch of desloratadine orally disintegrating tablets in the 2.5-mg and 5-mg strengths. The drug is a generic version of Merck's Clarinex Reditabs and is available in unit-dose packages of 30.

The branded version of the drug had sales of about $5.3 million during the 12-month period that ended in November 2012, according to IMS Health.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.

The FDA announced the approval of Avastin (bevacizumab) combined with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy for treating colorectal cancer that has spread to other parts of the body, also known as metastatic colorectal cancer, or mCRC.

The drug is also approved for treating lung cancer, kidney cancer and brain cancer.

MISSISSAUGA, Ontario — Canadian pharmacy retailer Rexall has unveiled its new flagship private brand, Be.better, a line of more than 100 products available exclusively at the more than 300 corporate Rexall and Rexall Pharma Plus stores.

SAN CLEMENTE, Calif. — Hero Nutritionals on Wednesday introduced two sugar-free vitamins to its Yummi Bears line that are naturally sweetened with lo han fruit and inulin fiber.

“Overall the gummy vitamin category is up by 19% year over year, with the new sugar-free trend emerging," stated Claire Polson, national sales and marketing manager for Hero Nutritionals. “Additionally, the supplement alternative sweetener category grew by 10%, with the children’s multivitamin category driving it at 23% growth as compared to 2011.”

ANN ARBOR, Mich. — A new study indicated that some parents may not be sufficiently concerned about misuse of narcotic painkillers by children and teenagers.

BALTIMORE — The Food and Drug Administration has approved a generic contraceptive made by Lupin Pharmaceuticals, the drug maker said Tuesday.

Lupin announced the approval of levonorgestrel and ethinyl estradiol tablets in the 0.1 mg/0.02 mg strength, a generic version of Watson Labs' Lutera.

Lutera had sales of about $103.6 million during the 12-month period that ended in September 2012, according to IMS Health.

NEW YORK — While regulations for biosimilars work their way through the Food and Drug Administration, state governments are already looking at legislation concerning the substitution of biosimilars for their branded counterparts, according to a legal affairs blog focused on the FDA.

In a post Friday on FDA Law Blog, the official blog of the law firm Hyman, Phelps & McNamara, attorney Kurt Karst wrote that several states were laying the groundwork for such legislation, recalling state-level antisubstitution laws targeting generics that were adopted in the 1970s.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

BI Pharmaceuticals is conducting the "HCVerso" trial of an HCV drug that combines faldaprevir, the experimental compound BI 207127 and ribavirin. The company has established trial sites in more than 25 states.